Importantly, MDM2 overexpression and p53 mutations typically occur as mutually exclusive events, reinforcing the idea that cancer phenotypes are often driven by disruptions in the p53-MDM2 interaction (Oliner et al., 1992[156], 2016[158]; Bond et al., 2004[16]). This evidence concerns the gene TP53 and cancer.